$HTBX breakout candle $2.49 Nasdaq CM very low f
Post# of 103036
Posted On: 11/27/2016 6:00:08 PM
$HTBX breakout candle $2.49
Nasdaq CM
very low float
Website
Shares Outstanding 23.88M
Float 17.6M
% Held by Insiders 30.02%
% Held by Institutions 24.60%
Shares Short 1.21M
Short Ratio 2.02
Short % of Float 8.73%
Shares Short (prior month) 1.09M
10-Q 11/10/16
Headlines
and filings
Heat Biologics, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel allogeneic off-the-shelf cellular therapeutic vaccines for a range of cancers and infectious diseases in the United States. The company develops its products based on T cell-stimulating platform technologies, including immune pan-antigen cytotoxic therapy, a platform technology designed to educate and stimulate the immune system against specific disease targets, such as cancer cells; and combination pan-antigen cytotoxic therapy, a platform technology that combines a pan-antigen T cell activating vaccine and a T cell co-stimulator in a single product. Its product candidates include viagenpumatucel-L (HS-110) that is in Phase 2 clinical trials for the treatment of non-small cell lung cancer; and vesigenurtacel-L (HS-410), which is in Phase 1b clinical trials for the treatment of non-muscle invasive bladder cancer. The company was founded in 2008 and is based in Durham, North Carolina
Nasdaq CM
very low float
Website
Shares Outstanding 23.88M
Float 17.6M
% Held by Insiders 30.02%
% Held by Institutions 24.60%
Shares Short 1.21M
Short Ratio 2.02
Short % of Float 8.73%
Shares Short (prior month) 1.09M
10-Q 11/10/16
Headlines
and filings
Heat Biologics, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel allogeneic off-the-shelf cellular therapeutic vaccines for a range of cancers and infectious diseases in the United States. The company develops its products based on T cell-stimulating platform technologies, including immune pan-antigen cytotoxic therapy, a platform technology designed to educate and stimulate the immune system against specific disease targets, such as cancer cells; and combination pan-antigen cytotoxic therapy, a platform technology that combines a pan-antigen T cell activating vaccine and a T cell co-stimulator in a single product. Its product candidates include viagenpumatucel-L (HS-110) that is in Phase 2 clinical trials for the treatment of non-small cell lung cancer; and vesigenurtacel-L (HS-410), which is in Phase 1b clinical trials for the treatment of non-muscle invasive bladder cancer. The company was founded in 2008 and is based in Durham, North Carolina
(0)
(0)Scroll down for more posts ▼